Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jul;36(1):155-8.
doi: 10.1016/j.ejcts.2008.12.055.

Thoracic metastasectomy for thyroid malignancies

Affiliations
Review

Thoracic metastasectomy for thyroid malignancies

John Roland Porterfield et al. Eur J Cardiothorac Surg. 2009 Jul.

Abstract

Objective: To better define early and long-term outcomes of patients undergoing thoracic metastasectomy for thyroid cancer.

Methods: We identified, reviewed, and analyzed the medical records of all patients who underwent thoracic metastasectomy for thyroid cancer in our institution from 1971 to 2006.

Results: There were 48 patients (25 men, 23 women). A complete resection (R0) of all known disease was performed in 33 (69%) patients, while 15 (31%) underwent incomplete resection (R1 or R2). By histology, the majority were papillary 31 (65%), follicular 8 (17%), medullary 5 (10%), and Hürthle cell 4 (8%). Ninety percent were confined to a single side of the chest, with 10% presenting with bilateral metastases. Thoracotomy was performed in 28 (58%), sternotomy in 12 (25%), and thoracoscopy was used in 8 (17%). Operative mortality was zero and postoperative complications occurred in 8 patients (17%). There are currently 18 surviving patients from the cohort (37%) with a median follow-up of 10 years (range, 1 month to 17 years). The overall 5-year survival after thoracic metastasectomy was 60%. Based on histology, 5-year survival for papillary cancer was 64% compared to 37% for follicular and Hürthle cell neoplasms (p=0.03). All five medullary thyroid cancer patients were alive at 5 years. Five-year survival was also improved for patients less than 45 years old at the time of diagnosis of their initial thyroid malignancy (94% vs 49%; p=0.03). Disease-free interval of >3 years between initial thyroid malignancy diagnosis and thoracic metastasectomy demonstrated improved 5-year survival (67% vs 52%; p=0.01).

Conclusion: Pulmonary resection for thyroid metastasis is safe with low morbidity and mortality. Retrospective analysis demonstrates improved long-term survival in patients with papillary histology, longer disease-free interval (>3 years) and younger age at diagnosis of initial thyroid malignancy. Excellent long-term survival was also achievable in selected patients with medullary thyroid metastasis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Survival (death from any cause) by cell type. Zero time on the abscissa represents the date of thoracic metastasectomy.

References

    1. Burke JP, Hay I, Dignan F, Goellner JR, Achenbach SJ, Oberg AL, Melton LJ. Long-term trends in thyroid carcinoma: a population-based study in Olmsted County, Minnesota, 1935–1999. Mayo Clin Proc. 2005;80:753–758. - PubMed
    1. Mitchell I, Livingston EH, Chang AY, Holt S, Snyder WH, 3rd, Lingvay I, Nwariaku FE. Trends in thyroid cancer demographics and surgical therapy in the United States. Surgery. 2007;142:823–828. - PubMed
    1. Pak H, Gourgiotis L, Chang WI, Guthrie LC, Skarulis MC, Reynolds JC, Merino MJ, Schrump DS, Libutti SK, Alexander HR, Jr, Sarlis NJ. Role of metastasectomy in the management of thyroid carcinoma: the NIH experience. J Surg Oncol. 2003;82:10–18. - PubMed
    1. Lin JD, Chao TC, Chou SC, Hsueh C. Papillary thyroid carcinomas with lung metastases. Thyroid. 2004;14:1091–1096. - PubMed
    1. Protopapas AD, Nicholson AG, Vini L, Harmer CL, Goldstraw P. Thoracic metastasectomy in thyroid malignancies. Ann Thorac Surg. 2001;72:1906–1908. - PubMed

Publication types

MeSH terms